Issue link: https://www.e-digitaleditions.com/i/1532011
Analytical challenges and regulatory perspectives in the development of soft mist inhalers (SMIs); Point of view: The concept of an inhalable nanoparticle-based siRNA therapy for betacoronavirus; Previewing RDD® Europe 2025; Study evaluates extent of asthma in Sub-Saharan African adolescents; highlights need for diagnosis, treatment and management; and Asthma control in children overestimated by parents, physicians and assessment tools. 2 February 2025 Inhalation Inhalation (ISSN 1940-414X digital) is published seven times per year in January, February, April, June, August, October and December by Whipsnade and Loophole, LLC, P.O. Box 27092, Minneapolis, MN 55427 US. w w w . i n h a l a t i o n m a g . c o m February 2025 Volume 19 Number 1 Cover photo shows the MRX004 Soft Mist Inhaler, used in the development of advanced inhaled therapies. Courtesy of Merxin Ltd., No.1 Innovation Drive, King's Lynn, Norfolk, PE30 5BY, United Kingdom, Tel.: +44 1553 403070, info@merxin.com, www.merxin.com. product development/contract testing 11 Analytical challenges and regulatory perspectives in the development of soft mist inhalers (SMIs) David Stadermann, Sitaram Velaga and Herbert Wachtel 18 Issue focus: Product development/Contract testing 24 Point of view: The concept of an inhalable nanoparticle-based siRNA therapy for betacoronavirus infections Joschka T. Müller, Thomas Michler and Olivia M. Merkel formulation development/excipients 31 Special section: Formulation development/Excipients additional features 6 Cross-industry organizations: Inhalation's partners 10 Previewing RDD ® Europe 2025 35 Back pages: Study evaluates extent of asthma in Sub-Saharan African adolescents; highlights need for diagnosis, treatment and management Asthma control in children overestimated by parents, physicians and assessment tools departments 9 Industry news 33 Calendar 34 White papers and webinars